Loading ...
Sorry, an error occurred while loading the content.

4789Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C

Expand Messages
  • claudine intexas
    Dec 2, 2000
      Note: If you are interested in reading the entire
      article I can send it to you as a PDF attachment; just
      let me know.


      Decreased bone mineral density after therapy with
      alpha interferon in
      combination with ribavirin for chronic hepatitis C

      Journal of Hepatology 2000; 33: 812�817

      Jose� A. Soli�s-Herruzo 1 , Gregorio Castellano 1 ,
      Inmaculada Ferna�
      ndez 1
      , Raquel Mun� oz 1 and Federico Hawkins 2 of 1
      Gastroenterology and 2
      Endocrinology, Department of Medicine, Hospital
      Universitario ��12 de
      Octubre��, Universidad Complutense, Madrid, Spain

      As you may know, higher than normal rates of bone
      mineral density loss
      been seen in HIV for people on HAART. Studies have
      suggested PI and
      therapy may be associated with BMD loss. As well,
      cytokine dysfunction
      been hypothesized as associated with bone problems as
      well as with

      Background/Aims: Several thousand patients with
      chronic hepatitis C
      have been

      treated with interferon plus ribavirin. After
      observing a male patient

      developed severe bone loss during this treatment, we
      studied skeletal

      and bone mineral metabolism in patients on therapy
      with interferon plus

      ribavirin. Methods: Bone mineral density and
      biochemical bone

      markers were studied in 32 male patients (31�58 years
      old) treated for

      months with either interferon alone (group 1; no13) or
      interferon plus

      ribavirin (group 2; no19).

      Results: Bone mineral density was significantly lower
      in group 2

      g/cm 2 ) than in group 1 (1.108�0.08 g/cm 2 ,
      p�0.001). Likewise, T- Z-

      score values were also decreased in group 2 (T:
      �1.95�0.6. Z:

      compared with group 1 (T: 0.19�0.6; p�0.001. Z:
      0.26�0.6; p�0.001).
      Serum and

      urine biochemical bone markers were nor-mal in both
      groups. However,

      calcium excretion was decreased in patients on
      combined therapy.

      Conclusion: Treatment of chronic hepatitis C with
      interferon plus

      may induce bone loss. This secondary effect should be
      during the

      follow-up of these patients, since they may require
      therapies aimed at

      prevention or amelioration of these defects.

      Do You Yahoo!?
      Yahoo! Shopping - Thousands of Stores. Millions of Products.